Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × HER2 Negative Breast Cancer × Anastrozole × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 189 Neoplasms 12 Neoplasm Metastasis 12 Carcinoma, Intraductal, Noninfiltrating 8 Breast Neoplasms, Male 6 Breast Diseases 5 Breast Carcinoma In Situ 5 Advanced Breast Cancer 5 Triple Negative Breast Neoplasms 4 Ovarian Neoplasms 4 Endometrial Neoplasms 4 Neoplasms by Site 3 Breast Cancer Metastatic 3 Carcinoma, Non-Small-Cell Lung 2 Uterine Cervical Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumor 1 Skin Diseases 1 Sexual Dysfunction, Physiological 1 Seizures 1 Sarcoma 1 Recurrence 1 Quality of Life 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Osteoporosis 1 Multiple Endocrine Neoplasia Type 1 1 Low Grade Serous Ovarian Cancer 1 Locoregional Recurrence 1 Lethal Congenital Contracture Syndrome 2 1

Interventions

ribociclib 1 Tretinoin 1 Letrozole 1 Goserelin 1 Drug Therapy 1 Chemotherapy, Adjuvant 1 Anastrozole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06953882 2025-07-14

SELECT

Yale University

Phase 2 Recruiting

HER2 Negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡